Fear of Cancer ProgressionNCT07752992
A Brief Psychological Intervention for Carer Fear of Cancer Progression
A study testing Conquer Fear Carer Brief in people with Fear of Cancer Progression, run by University of Aarhus at 1 site in Denmark.
Trial summary
This study aims to evaluate the feasibility and acceptability of the Conquer Fear Carer Brief, a three-session psychological intervention targeting fear of cancer progression among caregivers of patients with metastatic prostate cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fear of Cancer Progression
- What is being tested?
- Conquer Fear Carer Brief
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 1 siteDenmark
- Study dates
- 15 Jun 2026to Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Self-identified caregiver of a patient with metastatic, non-curable cancer
- Aged ≥18 years
- Score in the clinical range (≥22) on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF)
- Score in the clinical range (>15) on the Brief Penn State Worry Questionnaire (PSWQ)
- Sufficient proficiency in Danish
- Able to provide informed consent
- Stable or no use of antidepressant or anxiolytic medication (i.e., stable dosage for ≥6 weeks)
- Able to participate in online-delivered therapy via a computer with a video camera
Who cannot join
- Severe psychiatric conditions (e.g., major depression) that would make participation in the intervention inappropriate
- Currently enrolled in psychotherapy or counseling targeting the same problem
- Substance abuse or dependence judged to require treatment
- Suicide risk requiring immediate psychiatric intervention or hospitalization
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Department of Psychology and Behavioural Sciences, Aarhus University
Aarhus, 8000
Cecilie R Buskbjerg, PhD, +4529842526, cdrc@psy.au.dk
About this study
Official title: Conquer Fear Carer Brief: A Brief Psychological Intervention for Fear of Cancer Progression in Caregivers of Patients With Metastatic Cancer: A Feasibility Study
This study aims to evaluate the feasibility and acceptability of the Conquer Fear Carer Brief, a three-session psychological intervention targeting fear of cancer progression among caregivers of patients with metastatic prostate cancer.
Read the detailed description
PRIMARY OBJECTIVE:
To evaluate the feasibility and acceptability of the Conquer Fear Carer Brief intervention among caregivers of patients with metastatic cancer.
Feasibility will be assessed based on the following criteria:
- A treatment dropout rate of < 20%,
- A consent rate of > 50% among eligible caregivers screened for participation,
- Recruitment of 14 caregivers within the defined study period,
- Decrease or stability of caregivers' self-reported fear of cancer progression, as assessed on the Fear of Cancer Recurrence Inventory (FCRI), adapted for caregivers of patients with cancer, from pre-intervention (T1) to post-intervention (T2) and follow-up (T3),
- Intervention delivery fidelity, defined as therapist adherence to key intervention principles, rated on a 0-2 scale. A random sample of 20% of sessions will be independently rated based on video recordings.
Acceptability will be assessed based on the following criteria:
- A mean sum score of ≥20 on the Client Satisfaction Questionnaire (CSQ),
- Absence of serious intervention-related negative effects, as assessed using, the Negative Effects Questionnaire (NEQ).
SECONDARY OBJECTIVES:
- To evaluate the direction of change on specified secondary outcomes among caregivers of patients with metastatic cancer
- To explore participants' understanding of the intervention content and ability to apply this in everyday life, assessed using a custom-designed questionnaire with open-ended responses.
DESCRIPTION:
The Conquer Fear Carer Brief intervention is based on the Australian metacognitive intervention Conquer Fear, which has demonstrated efficacy in reducing fear of cancer progression and recurrence among cancer survivors in Australia and Denmark (Butow et al., 2017; Tauber et al., 2022; 2024).
The Conquer Fear Carer Brief is a shortened, three-session, online-delivered adaptation targeting fear of cancer progression in caregivers of cancer patients.
STUDY DESIGN:
The study employs a within-subject design with a pre-intervention waiting period (T0-T1). Changes during the waiting period will be compared with changes during the intervention (T1-T2) and follow-up (T1-T3).
ASSESSMENT TIME POINTS:
Participants will complete self-report questionnaires at enrollment (baseline; T0), after a three-week waiting period (pre-treatment; T1), one week after the intervention (post-treatment: T2) and 12 weeks after the intervention (follow-up; T3). Brief session questionnaires will also be completed before each session (S1-S3) and after Session 1 (S1 post).
- Conditions
- Fear of Cancer Progression
- Being tested
- Conquer Fear Carer Brief
- Keywords
- Fear of Cancer Progression, Caregivers, Metacognitive therapy, Feasibility, Online-delivered psychological therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conquer Fear Carer BriefBehavioural
The intervention is delivered online by a psychologist or a master's-level student in psychology over three sessions during a 3-4-week period.
The three sessions are structured to enhance participants' abilities in Detached Mindfulness (DM), a cognitive technique used in Metacognitive Therapy that involves perceiving thoughts and feelings as passing events without engaging with them.
In Session 1, DM is introduced through dialogue, examples, and exercises. In session 2, Attention Training (AT) is introduced to support participants' ability to engage in DM through dialogue, examples, and exercises. In Session 3, DM and AT are reviewed and discussed depending on participants' needs, and their future application are discussed.
Participants apply the introduced techniques at home between sessions through assigned homework.
| Study group | Role | What they receive |
|---|---|---|
| Conquer Fear Carer Brief | Experimental | Metacognitive therapy delivered individually over 3 sessions. Receives: Behavioral: Conquer Fear Carer Brief |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intervention feasibility: Treatment dropout rate
Treatment dropout is defined as attending fewer than two of the three sessions and not completing the post-intervention (Time 2) questionnaire. Feasibility will be indicated by a dropout rate of <30%.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Intervention feasibility: Consent rate
Consent rate among eligible caregivers screened for participation will be evaluated. Feasibility will be indicated by a consent rate > 50%.
Measured: Baseline (Time 0)
Intervention feasibility: Successfull recruitment
The number of included participants will be recorded. Feasibility will be indicated by the recruitment of 14 caregivers within the defined study period.
Measured: Baseline (Time 0)
Intervention feasibility: Change in fear of cancer progression from pre-intervention (Time 1) to post-intervention (Time 2) and follow-up (Time 3)
Participant-reported fear of cancer progression will be assessed in the beginning of each session using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF), adapted to measure fear of cancer progression in caregivers of patients with cancer. The FCRI-SF is a 9-item measure rated on a scale from 0 to 4, with total scores ranging from 0 to 45. Higher scores indicate greater fear of cancer progression.
Feasibility will be indicated by stability or decrease throughout the defined time frame.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Intervention Feasibility: Intervention delivery fidelity
Therapist adherence to key intervention principles (i.e., delivery of core therapeutic elements as intended) will be rated on a 0-2 scale. A random sample of 20% of sessions will be independently rated based on video recordings.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Intervention acceptability: Retrospective satisfaction
Participant-reported treatment satisfaction will be assessed using the 8-item Client Satisfaction Questionnaire (CSQ). Items are rated on a scale from 1 to 4, with total scores ranging from 8 to 32. Higher scores indicate greater treatment satisfaction.
Acceptability will be indicated by a mean sum score of ≥20.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Intervention acceptability: Negative effects
Participant-reported negative effects will be assessed using the 20-item Negative Effects Questionnaire (NEQ).
First, respondents indicate whether each negative effect occurred during treatment using a yes/no format. Second, they rate the severity of each endorsed negative effect on a scale from 0 to 4, with higher scores indicating greater severity. Third, respondents attribute each negative effect either to "the treatment I received" or to "other circumstances".
Acceptability will be indicated by an absence of serious adverse events attributed to the intervention.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Secondary outcomes (14)
Anxiety
Participant-reported anxiety will be assessed using the 7-item anxiety subscale of the Hospital Anxiety and Depression Scale (HADS). Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 28. Higher scores indicate greater anxiety.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Cancer-specific distress
Participant-reported cancer-specific distress will be assessed using the 22-item Impact of Events Scale Revised (IES-R). Items are rated on a scale from 0 to 4, with total scores ranging from 0 to 88. Higher scores indicate greater distress.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Well-being
Participant-reported well-being will be assessed using the 5-item World Health Organization-Five Well-Being Index (WHO-5). Items are rated on a scale from 0 to 5, with total scores ranging from 0 to 100. Higher scores indicate greater well-being.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Caregiver reaction
Participant-reported caregiver reaction will be assessed using the 24-item Caregiver Reaction Assessment (CRA). Items are rated on a scale from 1 to 5. The CRA comprises five subscales: Self Esteem, Lack of Family Support, Impact on Finances, Impact on Schedule, Impact on Health.
For the Self Esteem subscale, higher scores indicate greater esteem (positive outcome). For the remaining four subscales, higher scores indicate greater caregiver burden (negative outcome).
Subscale scores are calculated as mean item scores ranging from 1.0 to 5.0.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Sleep health
Participant-reported sleep health will be assessed using the 6-item RU SATED.
RU-SATED stands for:
Satisfaction: Are you satisfied with your sleep? Alertness: Do you stay awake all day without dozing? Timing: Are you asleep (or trying to sleep) between 2 am and 4 am? Efficiency: Do you spend less than 30 minutes awake at night (including time to fall asleep and awakenings)? Duration: Do you sleep between 6 and 8 hours per day?
Items are rated on a scale from 0 to 4, with total scores ranging from 0 to 24. Higher scores represent greater sleep health.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Decentering from thoughts
Participant-reported decentering from thoughts will be assessed using the 11-item decentering subscale of the Experience Questionnaire (EQ). Items are rated on a scale from 1 to 5, with total scores ranging from 11 to 55. Higher scores indicate greater levels of decentering.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Valued living
Participant-reported valued living will be assessed using the 10-item Valuing Questionnaire (VQ). Items are rated on a scale from 0 to 6. The measure yields two subscales, Progress and Obstruction, each with total scores ranging from 0 to 30. For the Progress subscale, higher scores indicate closer alignment between one's values and actions (positive outcome). For the Obstruction subscale, higher scores indicate greater interference with living consistently with one's values (negative outcome).
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Worry
Participant-reported worry will be assessed using the 16-item Penn State Worry Questionnaire (PSWQ). Items are rated on a scale from 1 to 5, with total scores ranging from 16 to 80. Higher scores indicate greater worry.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Metacognitions
Participant-reported metacognitions will be assessed using the 30-item Metacognitions Questionnaire (MCQ-30). Items are rated on a scale from 1 to 5, with total scores ranging from 30 to 120. Higher scores indicate greater levels of unhelpful metacognitions.
Measured: Follow-up approximately 22 weeks after baseline (Time 3)
Treatment expectancy
Participant-reported treatment expectancy will be assessed using the 6-item Credibility/Expectancy Questionnaire (CEQ). Items are rated on a scale from 1 to 9. The measure yields two subscales, Credibility and Outcome Expectation, with total scores for each subscale ranging from 3 to 27. Higher scores indicate greater perceived credibility and outcome expectancy.
Measured: Session 1 at approximately day 28
Fear of cancer progression
Participant-reported fear of cancer progression will be assessed in the beginning of each session using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF), adapted to measure fear of cancer progression in caregivers of patients with cancer. The FCRI-SF is a 9-item measure rated on a scale from 0 to 4, with total scores ranging from 0 to 45. Higher scores indicate greater fear of cancer progression.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Metacognitions
Participant-reported metacognitions will be assessed in the beginning of each session using the 30-item Metacognitions Questionnaire (MCQ-30). Items are rated on a scale from 1 to 5, with total scores ranging from 30 to 120. Higher scores indicate greater levels of unhelpful metacognitions.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Distance from thoughts
Participant-reported distance from thoughts will be assessed in the beginning of each session using the 11-item decentering subscale of the Experience Questionnaire (EQ). Items are rated on a scale from 1 to 5, with total scores ranging from 11 to 55. Higher scores indicate greater levels of decentering.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Treatment understanding and everyday application
Participant-reported treatment understanding and everyday application will be assessed using six custom items. Four items are rated on a scale ranging from 1 (not at all) to 5 (to a high degree) and assess the extent to which participants (1) understood Detached Mindfulness (DM), (2) felt self-efficacious in applying DM in everyday life, (3) found DM helpful, and (4) applied DM in everyday life. The remaining two items are open-ended questions asking participants (1) to describe how they would explain DM to a friend and (2) to describe how and when they apply DM in everyday life.
Measured: Post-treatment approximately 7 weeks after baseline (Time 2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study start15 Jun 2026
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fear of Cancer ProgressionStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Within-subject repeated-measures design including a pre-intervention waiting period
- Masking
- None (open label)
- Enrolment
- 14 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cecilie Buskbjerg, University of Aarhus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07752992
- Sponsor's protocol ID
- BSS-2025-041-S1
- Status last verified
- Sep 2026
- First submitted
- 24 Apr 2026
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to the sensitive nature of the data and the associated risk of re-identification, even after de-identification. Data sharing is not consistent with the informed consent provided by participants. Only aggregate data may be made available for research purposes upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conquer Fear Carer Brief: A Brief Psychological Intervention for Fear of Cancer Progression in Caregivers of Patients With Metastatic Cancer: A Feasibility Study
- ClinicalTrials.gov ID
- NCT07752992
- Acronym / sponsor ID
- BSS-2025-041-S1
- Conditions
- Fear of Cancer Progression
- Keywords
- Fear of Cancer Progression, Caregivers, Metacognitive therapy, Feasibility, Online-delivered psychological therapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 14 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Study start
- 15 Jun 2026 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 7 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the feasibility and acceptability of the Conquer Fear Carer Brief, a three-session psychological intervention targeting fear of cancer progression among caregivers of patients with metastatic prostate cancer.
Detailed description
PRIMARY OBJECTIVE:
To evaluate the feasibility and acceptability of the Conquer Fear Carer Brief intervention among caregivers of patients with metastatic cancer.
Feasibility will be assessed based on the following criteria:
- A treatment dropout rate of < 20%,
- A consent rate of > 50% among eligible caregivers screened for participation,
- Recruitment of 14 caregivers within the defined study period,
- Decrease or stability of caregivers' self-reported fear of cancer progression, as assessed on the Fear of Cancer Recurrence Inventory (FCRI), adapted for caregivers of patients with cancer, from pre-intervention (T1) to post-intervention (T2) and follow-up (T3),
- Intervention delivery fidelity, defined as therapist adherence to key intervention principles, rated on a 0-2 scale. A random sample of 20% of sessions will be independently rated based on video recordings.
Acceptability will be assessed based on the following criteria:
- A mean sum score of ≥20 on the Client Satisfaction Questionnaire (CSQ),
- Absence of serious intervention-related negative effects, as assessed using, the Negative Effects Questionnaire (NEQ).
SECONDARY OBJECTIVES:
- To evaluate the direction of change on specified secondary outcomes among caregivers of patients with metastatic cancer
- To explore participants' understanding of the intervention content and ability to apply this in everyday life, assessed using a custom-designed questionnaire with open-ended responses.
DESCRIPTION:
The Conquer Fear Carer Brief intervention is based on the Australian metacognitive intervention Conquer Fear, which has demonstrated efficacy in reducing fear of cancer progression and recurrence among cancer survivors in Australia and Denmark (Butow et al., 2017; Tauber et al., 2022; 2024).
The Conquer Fear Carer Brief is a shortened, three-session, online-delivered adaptation targeting fear of cancer progression in caregivers of cancer patients.
STUDY DESIGN:
The study employs a within-subject design with a pre-intervention waiting period (T0-T1). Changes during the waiting period will be compared with changes during the intervention (T1-T2) and follow-up (T1-T3).
ASSESSMENT TIME POINTS:
Participants will complete self-report questionnaires at enrollment (baseline; T0), after a three-week waiting period (pre-treatment; T1), one week after the intervention (post-treatment: T2) and 12 weeks after the intervention (follow-up; T3). Brief session questionnaires will also be completed before each session (S1-S3) and after Session 1 (S1 post).
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Within-subject repeated-measures design including a pre-intervention waiting period
| Arm | Type | Receives |
|---|---|---|
| Conquer Fear Carer Brief | Experimental | Behavioral: Conquer Fear Carer BriefMetacognitive therapy delivered individually over 3 sessions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Self-identified caregiver of a patient with metastatic, non-curable cancer
- Aged ≥18 years
- Score in the clinical range (≥22) on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF)
- Score in the clinical range (>15) on the Brief Penn State Worry Questionnaire (PSWQ)
- Sufficient proficiency in Danish
Key exclusion criteria (4 listed)
- Severe psychiatric conditions (e.g., major depression) that would make participation in the intervention inappropriate
- Currently enrolled in psychotherapy or counseling targeting the same problem
- Substance abuse or dependence judged to require treatment
- Suicide risk requiring immediate psychiatric intervention or hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conquer Fear Carer BriefThe intervention is delivered online by a psychologist or a master's-level student in psychology over three sessions during a 3-4-week period. The three sessions are structured to enhance participants' abilities in Detached Mindfulness (DM), a cognitive technique used in Metacognitive Therapy that involves perceiving thoughts and feelings as passing events without engaging with them. In Session 1, DM is introduced through dialogue, examples, and exercises. In session 2, Attention Training (AT) is introduced to support participants' ability to engage in DM through dialogue, examples, and exercises. In Session 3, DM and AT are reviewed and discussed depending on participants' needs, and their future application are discussed. Participants apply the introduced techniques at home between sessions through assigned homework. | Behavioural | Conquer Fear Carer Brief |
Primary outcome
Intervention feasibility: Treatment dropout rate
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Treatment dropout is defined as attending fewer than two of the three sessions and not completing the post-intervention (Time 2) questionnaire. Feasibility will be indicated by a dropout rate of <30%.
Intervention feasibility: Consent rate
Time frame: Baseline (Time 0)
Consent rate among eligible caregivers screened for participation will be evaluated. Feasibility will be indicated by a consent rate > 50%.
Intervention feasibility: Successfull recruitment
Time frame: Baseline (Time 0)
The number of included participants will be recorded. Feasibility will be indicated by the recruitment of 14 caregivers within the defined study period.
Intervention feasibility: Change in fear of cancer progression from pre-intervention (Time 1) to post-intervention (Time 2) and follow-up (Time 3)
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Participant-reported fear of cancer progression will be assessed in the beginning of each session using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF), adapted to measure fear of cancer progression in caregivers of patients with cancer. The FCRI-SF is a 9-item measure rated on a scale from 0 to 4, with total scores ranging from 0 to 45. Higher scores indicate greater fear of cancer progression. Feasibility will be indicated by stability or decrease throughout the defined time frame.
Intervention Feasibility: Intervention delivery fidelity
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Therapist adherence to key intervention principles (i.e., delivery of core therapeutic elements as intended) will be rated on a 0-2 scale. A random sample of 20% of sessions will be independently rated based on video recordings.
Intervention acceptability: Retrospective satisfaction
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Participant-reported treatment satisfaction will be assessed using the 8-item Client Satisfaction Questionnaire (CSQ). Items are rated on a scale from 1 to 4, with total scores ranging from 8 to 32. Higher scores indicate greater treatment satisfaction. Acceptability will be indicated by a mean sum score of ≥20.
Intervention acceptability: Negative effects
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Participant-reported negative effects will be assessed using the 20-item Negative Effects Questionnaire (NEQ). First, respondents indicate whether each negative effect occurred during treatment using a yes/no format. Second, they rate the severity of each endorsed negative effect on a scale from 0 to 4, with higher scores indicating greater severity. Third, respondents attribute each negative effect either to "the treatment I received" or to "other circumstances". Acceptability will be indicated by an absence of serious adverse events attributed to the intervention.
14 secondary outcomes
Anxiety
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Cancer-specific distress
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Well-being
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Caregiver reaction
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Sleep health
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Decentering from thoughts
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Valued living
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Worry
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Metacognitions
Time frame: Follow-up approximately 22 weeks after baseline (Time 3)
Treatment expectancy
Time frame: Session 1 at approximately day 28
Fear of cancer progression
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Metacognitions
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Distance from thoughts
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Treatment understanding and everyday application
Time frame: Post-treatment approximately 7 weeks after baseline (Time 2)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to the sensitive nature of the data and the associated risk of re-identification, even after de-identification. Data sharing is not consistent with the informed consent provided by participants. Only aggregate data may be made available for research purposes upon reasonable request.
Related trials for Fear of Cancer Progression
Active, not recruiting
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8
Active, not recruiting
A Nurse-Led Intervention for Fear of Progression in Advanced Cancer
Advanced Lung Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm
Recruiting
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Recruiting
Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches
Advanced or Metastatic Cancer, Fear of Cancer Progression
Recruiting
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conquer Fear Carer Brief in people with Fear of Cancer Progression, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cecilie R Buskbjerg, PhD (+4529842526, cdrc@psy.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intervention feasibility: Treatment dropout rate (time frame: Post-treatment approximately 7 weeks after baseline (Time 2)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.